Nowa wersja platformy jest już dostępna.
Przejdź na


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
2014 | 9 | 2 | 348-356
Tytuł artykułu

Prevalence and predictors of potential drug-drug interactions

Treść / Zawartość
Warianty tytułu
Języki publikacji
Słowa kluczowe

Opis fizyczny
  • Department of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Kragujevac, Svetozara Markovica 69, 34000, Kragujevac, Serbia
  • Department of Pharmacology and Toxicology, Faculty of Medicine, University of Novi Sad, Hajduk Veljkova 3, 21000, Novi Sad, Serbia
  • [1] Michalets E.L., Williams C.R., Drug interactions with cisapride: clinical implications, Clin. Pharmacokinet., 2000, 39, 49–75[Crossref]
  • [2] Juntti-Patinen L., Neuvonen P.J., Drug-related deaths in a university central hospital, Eur. J. Clin. Pharmacol., 2002, 58, 479–482[Crossref]
  • [3] Pirmohamed M., James S., Meakin S., Green C., Scott A.K., Walley T.J., et al., Adverse drug reactions as cause of admission to hospital: prospective analysis of 18820 patients, BMJ., 2004, 329, 15–19
  • [4] Zed P.J., Abu-Laban R.B., Balen R.M., Loewen P.S., Hohl C.M., Brubacher J.R., et al., Incidence, severity and preventability of medication-related visits to the emergency department: a prospective study, CMAJ., 2008, 178, 1563–1569[Crossref]
  • [5] Patel P., Zed P.J., Drug-related visits to the emergency department: how big is the problem?, Pharmacotherapy, 2002, 22, 915–923[Crossref]
  • [6] Guédon-Moreau L., Ducrocq D., Duc M.F., Quieureux Y., L’Hôte C., Deligne J., et al., Absolute contraindications in relation to potential drug interactions in outpatient prescriptions: analysis of the first five million prescriptions in 1999, Eur. J. Clin. Pharmacol., 2003, 59, 689–695[Crossref]
  • [7] Huang S.M., Lesko L.J., Drug-drug, drug-dietary supplement, and drug-citrus fruit and other food interactions: what have we learned?, J. Clin. Pharmacol. 2004, 44, 559–569[Crossref]
  • [8] Moura C.S., Acurcio F.A., Belo N.O., Drug-drug interactions associated with length of stay and cost of hospitalization, J. Pharm. Pharm. Sci., 2009, 12, 266–272
  • [9] Einarson T.R., Metge C.J., Iskedjian M., Mukherjee J., An examination of the effect of cytochrome P450 drug interactions of hydroxymethylglutarylcoenzyme A reductase inhibitors on health care utilization: a Canadian population-based study, Clin. Ther. 2002, 24, 2126–2136[Crossref]
  • [10] Saurat J.H., Guérin A., Yu A.P., Latremouille-Viau D., Wu E.Q., Gupta S.R., et al., High prevalence of potential drug-drug interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasis: associated clinical and economic outcomes in real-world practice, Dermatology, 2010, 220, 128–137[Crossref]
  • [11] Pergolizzi J.V. Jr., Labhsetwar S.A., Amy Puenpatom R., Ben-Joseph R., Ohsfeldt R., Summers K.H., Economic impact of potential CYP450 pharmacokinetic drug-drug interactions among chronic low back pain patients taking opioids, Pain Pract., 2012, 12, 45–56[Crossref]
  • [12] Pergolizzi J.V. Jr., Labhsetwar S.A., Puenpatom R.A., Ben-Joseph R., Ohsfeldt R., Summers K.H., Economic impact of potential drug-drug interactions among osteoarthritis patients taking opioids, Pain Pract., 2012, 12, 33–44[Crossref]
  • [13] Hamilton R.A., Briceland L.L., Andritz M.H., Frequency of hospitalization after exposure to known drug-drug interactions in a Medicaid population, Pharmacotherapy, 1998, 18, 1112–1120
  • [14] Obreli-Neto P.R., Nobili A., de Oliveira Baldoni A., Guidoni C.M., de Lyra Junior D.P., Pilger D., et al., Adverse drug reactions caused by drug-drug interactions in elderly outpatients: a prospective cohort study, Eur. J. Clin. Pharmacol., 2012, 68, 1667–1676[Crossref]
  • [15] van Roon E.N., Flikweert S., le Comte M., Langendijk P.N., Kwee-Zuiderwijk W.J., Smits P., et al., Clinical relevance of drug-drug interactions: a structured assessment procedure, Drug Saf., 2005, 28, 1131–1139[Crossref]
  • [16] Tatro D.S., Drug Interaction Facts? 2012 - The authority on drug interactions, Facts and Comparasions, St. Louis, Wolters Kluwer Health, 2011
  • [17] Aparasu R., Baer R., Aparasu A., Clinically important potential drug-drug interactions in outpatient settings, Res. Social. Adm. Pharm., 2007, 3, 426–437[Crossref]
  • [18] Grönroos P.E., Irjala K.M., Huupponen R.K., Scheinin H., Forsström J., Forsström J.J., A medication database a tool for detecting drug interactions in hospital, Eur. J. Clin. Pharmacol., 1997, 53, 13–17[Crossref]
  • [19] Merlo J., Liedholm H., Lindblad U., Björck-Linné A., Fält J., Lindberg G., et al., Prescriptions with potential drug interactions dispensed at Swedish pharmacies in January 1999: cross sectional study, BMJ., 2001, 323, 427–428[Crossref]
  • [20] Bergendal L., Friberg A., Schaffrath A., Potential drug-drug interactions in 5125 mostly elderly outpatients in Gothenburg, Sweden, Pharm. World Sci., 1995, 17, 152–157[Crossref]
  • [21] Costa A.J., Potential drug interactions in an ambulatory geriatric population, Fam. Pract., 1991, 8, 234–236[Crossref]
  • [22] Obreli Neto P.R., Nobili A., Marusic S., Pilger D., Guidoni C.M., Baldoni Ade O., et al., Prevalence and predictors of potential drug-drug interactions in the elderly: a cross-sectional study in the brazilian primary public health system, J. Pharm. Pharm. Sci., 2012, 15, 344–354
  • [23] Björkman I.K., Fastbom J., Schmidt I.K., Bernsten C.B., Pharmaceutical Care of the Elderly in Europe Research (PEER) Group, Drug-drug interactions in the elderly, Ann. Pharmacother., 2002, 36, 1675–1681[Crossref]
  • [24] Janchawee B., Wongpoowarak W., Owatranporn T., Chongsuvivatwong V., Pharmacoepidemiologic study of potential drug interactions in outpatients of a university hospital in Thailand, J. Clin. Pharm. Ther., 2005, 30, 13–20[Crossref]
  • [25] Cruciol-Souza J.M., Thomson J.C., Prevalence of potential drug-drug interactions and its associated factors in a Brazilian teaching hospital, J. Pharm. Pharm. Sci., 2006, 9, 427–433
  • [26] Doubova-Dubova S.V., Reyes-Morales H., Torres-Arreola Ldel P., Suárez-Ortega M., Potential drugdrug and drug-disease interactions in prescriptions for ambulatory patients over 50 years of age in family medicine clinics in Mexico City, BMC. Health Serv. Res., 2007, 7, 147[Crossref]
  • [27] Nobili A., Pasina L., Tettamanti M., Lucca U., Riva E., Marzona I., et al., Potentially severe drug interactions in elderly outpatients: results of an observational study of an administrative prescription database, J. Clin. Pharm. Ther., 2009, 34, 377–386[Crossref]
  • [28] Lin C.F., Wang C.Y., Bai C.H., Polypharmacy, aging and potential drug-drug interactions in outpatients in Taiwan: a retrospective computerized screening study, Drugs Aging, 2011, 28, 219–225[Crossref]
  • [29] Bjerrum L., Andersen M., Petersen G., Kragstrup J., Exposure to potential drug interactions in primaryhealth care, Scand. J. Prim. Health Care., 2003, 21, 153–158[Crossref]
  • [30] Johnell K., Klarin I., The relationship between number of drugs and potential drug-drug interactions in the elderly: a study of over 600000 elderly patients from the Swedish Prescribed Drug Register, Drug Saf., 2007, 30, 911–918[Crossref]
  • [31] Gagne J.J., Maio V., Rabinowitz C., Prevalence and predictors of potential drug-drug interactions in Regione Emilia-Romagna, Italy, J. Clin. Pharm. Ther., 2008, 33, 141–151[Crossref]
  • [32] Janchawee B., Owatranporn T., Mahatthanatrakul W., Chongsuvivatwong V., Clinical drug interactions in outpatients of a university hospital in Thailand, J. Clin. Pharm. Ther., 2005, 30, 583–590[Crossref]
  • [33] Carthy P., Harvey I., Brawn R., Watkins C., A study of factors associated with cost and variation in prescribing among GPs, Fam. Pract., 2000, 17, 36–41[Crossref]
  • [34] Rahmner P.B., Gustafsson L.L., Larsson J., Rosenqvist U., Tomson G., Holmström I., Variations in understanding the drug-prescribing process: a qualitative study among Swedish GPs, Fam. Pract., 2009, 26, 121–127[Crossref]
  • [35] Wun Y.T., Chan C.S., Dickinson J.A., Determinants of physicians’ attitude towards prescribing, J. Clin. Pharm. Ther., 2002; 27, 57–65[Crossref]
  • [36] WHO Collaborating Centre for Family of International Classifications. International Classification of Diseases. Available from: Accessed: 2012 December
  • [37] WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index. Available from: Accessed: 2012 December
  • [38] Fulda T.R., Valuck R.J., Zanden J.V., Parker S., Byrns P.J., Disagreement among drug compendia on inclusion and ratings of drug-drug interactions, Curr. Ther. Res., 2000, 61, 540–548[Crossref]
  • [39] Vitry A.I., Comparative assessment of four drug interaction compendia, Br. J. Clin. Pharmacol., 2007, 63, 709–714[Crossref]
  • [40] Rätz-Bravo A.E., Tchambaz L., Krähenbühl-Melcher A., Hess L., Schlienger R.G., Krähenbühl S., Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy, Drug Saf., 2005, 28, 263–275[Crossref]
  • [41] Chatsisvili A., Sapounidis I., Pavlidou G., Zoumpouridou E., Karakousis V.A., Spanakis M., et al., Potential drug-drug interactions in prescriptions dispensed in community pharmacies in Greece, Pharm. World Sci., 2010, 32, 187–193[Crossref]
  • [42] Jones J.D., Mogali S., Comer S.D., Polydrug abuse: a review of opioid and benzodiazepine combination use, Drug Alcohol Depend., 2012, 125, 8–18[Crossref]
  • [43] Gelkopf M., Bleich A., Hayward R., Bodner G., Adelson M., Characteristics of benzodiazepine abuse in methadone maintenance treatment patients: a 1 year prospective study in an Israeli clinic, Drug Alcohol Depend., 1999, 55, 63–68
  • [44] Stitzer M.L., Griffiths R.R., McLellan A.T., Grabowski J., Hawthorne J.W., Diazepam use among methadone maintenance patients: patterns and dosages, Drug Alcohol Depend., 1981, 8, 189–199[Crossref]
  • [45] Teixeira J.J., Crozatti M.T., dos Santos C.A., Romano-Lieber N.S., Potential drug-drug interactions in prescriptions to patients over 45 years of age in primary care, southern Brazil, PloS One, 2012, 7, e47062[Crossref]
  • [46] Secoli S.R., Figueras A., Lebrão M.L., de Lima F.D., Santos J.L., Risk of potential drug-drug interactions among Brazilian elderly: a populationbased, cross-sectional study, Drugs Aging, 2010, 27, 759–770[Crossref]
  • [47] Rosholm J.U., Bjerrum L., Hallas J., Worm J., Gram L.F., Polypharmacy and the risk of drug-drug interactions among Danish elderly. A prescription database study, Dan. Med. Bull., 1998, 45, 210–213
  • [48] Hohl C.M., Dankoff J., Colacone A., Afilalo M., Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department, Ann. Emerg. Med., 2001, 38, 666–671[Crossref]
  • [49] Rambhade S., Chakarborty A., Shrivastava A., Patil U.K., Rambhade A., A survey on polypharmacy and use of inappropriate medications, Toxicol. Int., 2012, 19, 68–73[Crossref]
  • [50] Reason B., Terner M., Moses McKeag A., Tipper B., Webster G., The impact of polypharmacy on the health of Canadian seniors, Fam. Pact., 2012, 29, 427–432[Crossref]
  • [51] Veehof L.J., Stewart R.E., Meyboom-de Jong B., Haaijer-Ruskamp F.M., Adverse drug reactions and polypharmacy in the elderly in general practice, Eur. J. Clin. Pharmacol., 1999, 55, 533–536[Crossref]
  • [52] Lopez-Picazo J.J., Ruiz J.C., Sanchez J.F., Ariza A., Aguilera B., Lazaro D., et al., Prevalence and typology of potential drug interactions occuring in primary care patients, Eur. J. Gen. Pract., 2010, 16, 92–99[Crossref]
  • [53] Sloan R.W., Drug interactions, Am. Fam. Physician, 1983, 27, 229–238
Typ dokumentu
Identyfikator YADDA
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.